ClinicalTrials.gg
CompletedNCT02901925ABY-029Updated Dec 13, 2024Results posted

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

An Early Phase 1 interventional study of ABY-029 in Glioma, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Dartmouth-Hitchcock Medical Center · Early Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 853 studies in Glioma with a site in United States — 144 open to participants now, 231 under way, 6 of them phase 3. Glioma · United States.

Enrollment
538th of 739
14 · median 30
Started
2017
with 43 others
Phase 1
339 of 853
64 open now
Registered
487th of 853
by date

Among the 853 studies in Glioma with a site in United States, this one is the 538th largest by enrollment of the 739 interventional ones that give a count, is one of 44 that started in 2017, is one of 339 in phase 1, and was the 487th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

144 of the 853 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 853 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining.

The secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI and intraoperative probe relative to histopathology diagnosis, and other indicators (e.g. proliferation, infiltration, etc.) as the gold standard, and to measure the molecular uptake and concentration of ABY-029 in resected specimens.

Read the detailed description

The investigators plan a sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery.

The protocol is not a safety study since no physiological effects are expected at microdose levels of ABY-029. Rather, doses have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. No diagnostic or therapeutic intent is proposed, and administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.

03

Conditions studied

  • Glioma

Browse trials for

Keywords

  • ABY-029
  • Affibody
  • Molecular Fluorescence-Guided Surgery
  • Epidermal Growth Factor Receptor (EGFR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Preoperative diagnosis of recurrent high-grade glioma having EGFR positive tissue from prior surgery.
  2. Tumor judged to be suitable for open cranial resection based on preoperative imaging studies.
  3. Valid by subject.
  4. Age ≥ 18 years old.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women or women who are breast feeding.
  2. Patients on any experimental anti-EGFR targeted therapies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    ABY-029 1X dose group

    ABY-029 will be administered at the 1X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.

    Drug: ABY-029

  • Experimental
    ABY-029 3X dose group

    ABY-029 will be administered at the 3X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.

    Drug: ABY-029

  • Experimental
    ABY-029 6X dose group

    ABY-029 will be administered at the 6X dose level prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.

    Drug: ABY-029

Interventions

  • Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.

    Also known as: ABY-029 trifluoroacetate salt, IRDye® 800CW Maleimide labeled Affibody peptide

06

What researchers measure

Primary outcomes

  1. Fluorescence Signal Detection

    The primary study endpoint is to determine if the fluorescence signal from ABY-029, as measured by Biological Variance Ratio (BVR), can be detected in brain tissue during surgery. This will help researchers determine if ABY-029 functions well for imaging brain tumor tissue during surgery.

    Time frame: during procedure

Secondary outcomes

  1. Mean Tumor-to-background Ratio

    A secondary study endpoint is to calculate the ratio of the average (mean) fluorescence intensity of ABY-029 measured in the tumor, to the average (mean) fluorescence intensity of ABY-029 measured in the surrounding tissues in the brain during surgery. This will help researchers determine how well ABY-029 works for imaging tumor tissue.

    Time frame: during procedure

  2. Ex Vivo Fluorescence Intensity

    Another secondary study endpoint is to quantify the relationship between the dose of ABY-029 administered and the fluorescence intensity produced by ABY-029 in ex vivo tissue samples after they have been transferred to the pathology department. This endpoint will be measured in relative fluorescence units, and will help researchers conduct analyses on how well ABY-029 works for imaging in tissue following surgery.

    Time frame: post surgical

07

Results

Posted Dec 13, 2024

Participant flow

Participants were recruited and enrolled at 1 academic medical center between February 2017 and June 2021. Of 14 participants enrolled (patients met the inclusion criteria and signed the consent form), a total of 12 received the study drug and started the study across the 3 dose groups: 3 patients in the 1X dose group, 3 patients in the 3X dose group, and 6 patients in the 6X dose group.

Participant flow — Overall Study
MilestoneABY-029 1X Dose GroupABY-029 3X Dose GroupABY-029 6X Dose Group
Started336
Completed336
Not completed000

Outcome measures

PrimaryFluorescence Signal Detection

The primary study endpoint is to determine if the fluorescence signal from ABY-029, as measured by Biological Variance Ratio (BVR), can be detected in brain tissue during surgery. This will help researchers determine if ABY-029 functions well for imaging brain tumor tissue during surgery.

Time frame:
during procedure
Reported as:
Mean · Biological variance ratio
Fluorescence Signal Detection
Biological variance ratio1X Dose Group3X Dose Group6X Dose Group
Fluorescence Signal Detection6.2 ± 2.45.0 ± 1.28.8 ± 3.7
SecondaryMean Tumor-to-background Ratio

A secondary study endpoint is to calculate the ratio of the average (mean) fluorescence intensity of ABY-029 measured in the tumor, to the average (mean) fluorescence intensity of ABY-029 measured in the surrounding tissues in the brain during surgery. This will help researchers determine how well ABY-029 works for imaging tumor tissue.

Time frame:
during procedure
Reported as:
Mean · tumor-to-background ratio
Mean Tumor-to-background Ratio
tumor-to-background ratio1X Dose Group3X Dose Group6X Dose Group
Mean Tumor-to-background Ratio1.7 ± 0.12.1 ± 0.62.6 ± 0.7
SecondaryEx Vivo Fluorescence Intensity

Another secondary study endpoint is to quantify the relationship between the dose of ABY-029 administered and the fluorescence intensity produced by ABY-029 in ex vivo tissue samples after they have been transferred to the pathology department. This endpoint will be measured in relative fluorescence units, and will help researchers conduct analyses on how well ABY-029 works for imaging in tissue following surgery.

Time frame:
post surgical
Reported as:
Mean · relative fluorescence units
Ex Vivo Fluorescence Intensity
relative fluorescence units1X Dose Group3X Dose Group6X Dose Group
Ex Vivo Fluorescence Intensity61.4 ± 25.1215.2 ± 109.1884.1 ± 475.4

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABY-029 1X Dose Group0/3 (0%)0/3 (0%)0/3 (0%)
ABY-029 3X Dose Group0/3 (0%)0/3 (0%)0/3 (0%)
ABY-029 6X Dose Group0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ABY-029 1X Dose GroupABY-029 3X Dose GroupABY-029 6X Dose GroupTotal
<=18 years0000
Between 18 and 65 years1337
>=65 years2035
Sex: Female, Male
Sex: Female, Male(Participants)ABY-029 1X Dose GroupABY-029 3X Dose GroupABY-029 6X Dose GroupTotal
Female2046
Male1326
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ABY-029 1X Dose GroupABY-029 3X Dose GroupABY-029 6X Dose GroupTotal
Hispanic or Latino0000
Not Hispanic or Latino33612
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABY-029 1X Dose GroupABY-029 3X Dose GroupABY-029 6X Dose GroupTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White32611
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)ABY-029 1X Dose GroupABY-029 3X Dose GroupABY-029 6X Dose GroupTotal
United States33612
08

Study locations

1 site
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jun 2021, 52 months.

Results were first posted in Dec 2024, 3 years 5 months after primary completion.

Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's 52 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2016
First posted
Sep 15, 2016
StartActual
Feb 13, 2017
Primary completionActual
Jun 29, 2021
CompletionActual
Jun 29, 2021
Results first posted
Dec 13, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02901925
Collaborators
Dartmouth College, National Cancer Institute (NCI)
Responsible party
David W. Roberts (Principal Investigator, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Sep 15, 2016
Start date
Feb 13, 2017
Primary completion
Jun 29, 2021
Completion
Jun 29, 2021
Results posted
Dec 13, 2024
Last update
Dec 13, 2024

Study contacts

David W Roberts, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABY-029

Start the discussion